Article Text

Download PDFPDF
Paclitaxel–platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial
  1. H. Utsunomiya*,
  2. J. Akahira*,,
  3. S. Tanno*,
  4. T. Moriya,
  5. M. Toyoshima*,
  6. H. Niikura*,
  7. K. Ito*,
  8. Y. Morimura,
  9. Y. Watanabe§ and
  10. N. Yaegashi*
  1. *Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Sendai, Japan
  2. Department of Pathology, Tohoku University Graduate School of Medicine, Sendai, Japan
  3. Department of Obstetrics and Gynecology, Tuboi Hospital, Koriyama, Japan
  4. §Department of Obstetrics and Gynecology, Kinki University School of Medicine, Osakasayama, Japan
  1. Address correspondence and reprint requests to: Hitoshi Niikura, MD, Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan. Email: niikura{at}


The therapeutic effect of a combination of paclitaxel (PTX) and platinum (PLT) in ovarian clear cell adenocarcinoma (CC) patients with measurable disease has yet to be elucidated. In this study, we used retrospective review to evaluate the results of treatment with a combination of PTX and PLT in CC patients with measurable disease. A total of 28 patients with measurable residual CC (15 cases with primary disease, 13 cases with recurrent disease) treated with combination PTX-PLT chemotherapy was identified through medical records from ten institutions. Clinical response to chemotherapy was evaluated using Response Evaluation Criteria in Solid Tumors criteria. Of the 28 cases, 8 of 15 patients with primary disease (53.3%) and 3 of 13 patients with recurrent disease (23.1%) responded to PTX-PLT chemotherapy. The response rate for cases with late recurrent disease (>12 months) was 20% (1/5), whereas the rate was 25% (2/8) for cases with early recurrent (<12 months) or refractory disease. Our results indicate that the combination of PTX and PLT may have greater efficacy against CC than conventional PLT-based chemotherapy that does not include PTX.

  • chemotherapy
  • clear cell adenocarcinoma
  • ovary
  • paclitaxel
  • platinum

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.